WS #17006
Moderna has reported strong Q3 results, beating both top-line and bottom-line estimates and raising its full-year outlook. This performance stands out against the broader market rout, offering a rare bullish catalyst in the healthcare sector and demonstrating that biotech fundamentals can still defy macro headwinds. Corporate earnings are sending mixed signals, with Under Armour and TELUS missing EPS expectations or offering cautious outlooks, while Starwood Property Trust reported a GAAP loss. These results highlight ongoing challenges in consumer discretionary and commercial real estate, reinforcing the bearish view on economic resilience.
Moderna Earnings Beat
Moderna has reported strong Q3 results, beating both top-line and bottom-line estimates and raising its full-year outlook. This performance stands out against the broader market rout, offering a rare bullish catalyst in the healthcare sector and demonstrating that biotech fundamentals can still defy macro headwinds.
Corporate earnings are sending mixed signals, with Under Armour and TELUS missing EPS expectations or offering cautious outlooks, while Starwood Property Trust reported a GAAP loss. These results highlight ongoing challenges in consumer discretionary and commercial real estate, reinforcing the bearish view on economic resilience.